IBSA Pharma Inc, a company involved in topical treatment of acute pain and the treatment of hypothyroidism, has repurchased marketing and distribution rights for Flector (diclofenac epolamine) topical system 1.3% from United States-based Pfizer, it was reported on Tuesday.
With the reacquisition, IBSA is providing two prescription topical drugs, Flector and Licart, intended to treat acute pain due to minor strains, sprains, and contusions. IBSA says that both the products are produced under its strict Quality System control.
The marketing rights for Flector have reverted to IBSA effective January 2021. The company has taken a decision to reduce the price of Flector and offer significant patient savings programs. Licart is the first and only once-a-day topical nonsteroidal anti-inflammatory drug therapy approved by the FDA.
Orsini chosen as single-source specialty pharmacy partner for Glaukos' Epioxa
GE HealthCare's Photonova Spectra gains FDA clearance
Futura Medical reports positive home user test results for Eroxon and Intense variant
GSK secures Japan Orphan Drug status for lung cancer ADC
Belief BioMed enters exclusive partnership with Grand Life Sciences for haemophilia A treatment
Glaukos launches Epioxa to advance incision-free treatment for keratoconus
Sanofi's venglustat receives FDA Breakthrough Therapy designation for type 3 Gaucher disease
Sentynl Therapeutics and PRG S&T enter licensing agreement for potential HGPS treatment
CMIC agrees agentic AI partnership with Bluenote
Biofrontera reports Phase 2b data for Ameluz photodynamic therapy in acne vulgaris treatment